Contineum Therapeutics . Class A Common Stock Stock Forecast

Buy or Hold candidate since Jul 08, 2026 Loss -2.94%

The Contineum Therapeutics, Inc. Class A stock price fell by -1.68% on the last day (Friday, 10th Jul 2026) from $15.45 to $15.19. During the last trading day the stock fluctuated 4.45% from a day low at $14.84 to a day high of $15.50. The price has been going up and down for this period, and there has been a 13.7% gain for the last 2 weeks. Volume has increased on the last day by 3 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 279 thousand shares were bought and sold for approximately $4.24 million.

The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 5.55% during the next 3 months and, with a 90% probability hold a price between $12.23 and $17.40 at the end of this 3-month period.

CTNM Signals & Forecast

The Contineum Therapeutics, Inc. Class A stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $15.25. On a fall, the stock will find some support from the long-term average at approximately $13.33. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, June 30, 2026, and so far it has fallen -7.32%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Contineum Therapeutics, Inc. Class A stock

On the downside, the stock finds support just below today's level from accumulated volume at $14.19 and $13.30. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Contineum Therapeutics, Inc. Class A finds support just below today's level at $14.19. If this is broken, then the next support from accumulated volume will be at $13.30 and $13.25.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.660 between high and low, or 4.45%. For the last week, the stock has had daily average volatility of 6.16%.

Our recommended stop-loss: $14.50 (-4.56%) (This stock has very high daily movements and this gives very high risk. There is a sell signal from a pivot top found 7 days ago.)

Trading Expectations (CTNM) For The Upcoming Trading Day Of Monday 13th

For the upcoming trading day on Monday, 13th we expect Contineum Therapeutics, Inc. Class A Common Stock to open at $15.18, and during the day (based on 14 day Average True Range), to move between $14.68 and $15.70, which gives a possible trading interval of +/-$1.03 (+/-7.01%) up or down from last closing price. If Contineum Therapeutics, Inc. Class A Common Stock takes out the full calculated possible swing range there will be an estimated 7.01% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $15.53 (2.24%) than the support at $14.19 (6.58%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Contineum Therapeutics, Inc. Class A Common Stock stock A Buy?

Contineum Therapeutics, Inc. Class A holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold candidate.

Current score: 0.486 Hold/Accumulate Downgraded

Predicted Fair Opening Price

Predicted fair opening price on July 13, 2026 - $15.18 ( 0.0878%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk